-
ASH 2024 | Dr. He Huang’s Team Secures 8 Oral Presentations, Showcasing Chinese Excellence on the Global Stage
The highly anticipated 66th Annual Meeting of the American Society of Hematology (ASH) will take place in San Diego, USA, from December 7 to 10, 2024. Renowned as one of the largest and most comprehensive international academic events in hematology, the ASH Annual Meeting serves as a premier platform for advancing the frontiers of the…
-
Dr. Yishan Ye on Donor Selection Trends: Insights from China’s Allogeneic Hematopoietic Stem Cell Transplantation Practice and the EBMT-China
From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was held in Hangzhou, China, attracting leading experts, scholars, and industry leaders in cellular and immune therapies. This international platform not only fosters academic exchange but also showcases the latest research breakthroughs and drives progress in the field. During the conference, Dr.…
-
CTI 2024 | Professor Li Tang: Promising Horizons for CAR-T and mRNA Gene Therapy
From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) took place in Hangzhou, China. This global event brought together leading experts, scholars, and industry pioneers in cellular and immune therapies, serving as both an academic platform and a showcase for the latest research breakthroughs. During the conference, Hematology Frontier launched the…
-
AASLD 2024丨Weight-Loss Surgery vs. Medication: A 5-Year Mortality Comparison in MAFLD Patients
This multicenter retrospective study, conducted within the Banner Health System, included MAFLD patients identified via ICD codes who met at least one of five metabolic criteria. Eligible participants had undergone…
-
AASLD 2024丨Dr. Qing Xie’s Team: TMF Improves Efficacy and Safety in ALT-Normal Chronic HBV Patients—Midterm Results from the PROMOTE Study
The PROMOTE study (NCT05797714) is a prospective, multicenter, randomized, open-label, controlled trial involving 12 centers, including Ruijin Hospital. It assessed the efficacy and safety of TMF in ALT-normal chronic HBV…
-
CTI 2024丨Prof. Xi Zhang: New Developments and Challenges in Chronic Graft-Versus-Host Disease
From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) took place in Hangzhou, China, bringing together global leaders in cellular and immune therapies. This prestigious event served as a platform for academic exchange and a showcase for cutting-edge research in the field. During the conference, Prof. Xi Zhang from the Department…
-
How I Treat丨Prof. Fengkui Zhang: My Approach to Treating Severe Aplastic Anemia
Severe aplastic anemia (AA) remains a significant therapeutic challenge despite progress in its diagnosis and treatment. Issues such as difficulty in donor matching, side effects of immunosuppressive therapy (IST), and suboptimal hematologic responses demand continued exploration of innovative solutions. Prof. Fengkui Zhang of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical…
-
2024 Great Wall Hematology Forum丨Prof. Wenming Chen: Integrating Fundamentals and Clinical Practice to Foster Young Talent
On November 15–16, 2024, the “Annual Meeting of the Hematology Committee of the Chinese Medical Education Association—Great Wall Hematology Forum” was successfully held in Beijing. This conference brought together leading experts in hematology to discuss advancements in the diagnosis and treatment of hematological diseases, delve into the latest research findings, and explore the future direction…
Connecting Medical Expertise through Media